nodes	percent_of_prediction	percent_of_DWPC	metapath
Clavulanate—Cystitis haemorrhagic—Epirubicin—bone cancer	0.105	0.105	CcSEcCtD
Clavulanate—Cystitis haemorrhagic—Doxorubicin—bone cancer	0.0969	0.0969	CcSEcCtD
Clavulanate—Pain—Carboplatin—bone cancer	0.0426	0.0426	CcSEcCtD
Clavulanate—Hypokalaemia—Cisplatin—bone cancer	0.027	0.027	CcSEcCtD
Clavulanate—Jaundice cholestatic—Epirubicin—bone cancer	0.0239	0.0239	CcSEcCtD
Clavulanate—Jaundice cholestatic—Doxorubicin—bone cancer	0.0221	0.0221	CcSEcCtD
Clavulanate—Thrombophlebitis—Methotrexate—bone cancer	0.0188	0.0188	CcSEcCtD
Clavulanate—Thrombophlebitis—Epirubicin—bone cancer	0.0176	0.0176	CcSEcCtD
Clavulanate—Thrombophlebitis—Doxorubicin—bone cancer	0.0163	0.0163	CcSEcCtD
Clavulanate—Leukopenia—Cisplatin—bone cancer	0.016	0.016	CcSEcCtD
Clavulanate—Convulsion—Cisplatin—bone cancer	0.0155	0.0155	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.0147	0.0147	CcSEcCtD
Clavulanate—Anaphylactic shock—Cisplatin—bone cancer	0.0146	0.0146	CcSEcCtD
Clavulanate—Thrombocytopenia—Cisplatin—bone cancer	0.0143	0.0143	CcSEcCtD
Clavulanate—Eosinophilia—Methotrexate—bone cancer	0.0139	0.0139	CcSEcCtD
Clavulanate—Hypokalaemia—Epirubicin—bone cancer	0.0139	0.0139	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.0137	0.0137	CcSEcCtD
Clavulanate—Eosinophilia—Epirubicin—bone cancer	0.0131	0.0131	CcSEcCtD
Clavulanate—Hypokalaemia—Doxorubicin—bone cancer	0.0128	0.0128	CcSEcCtD
Clavulanate—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.0127	0.0127	CcSEcCtD
Clavulanate—Pain—Cisplatin—bone cancer	0.0125	0.0125	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.0125	0.0125	CcSEcCtD
Clavulanate—Eosinophilia—Doxorubicin—bone cancer	0.0121	0.0121	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.0117	0.0117	CcSEcCtD
Clavulanate—Haemoglobin—Methotrexate—bone cancer	0.0113	0.0113	CcSEcCtD
Clavulanate—Haemorrhage—Methotrexate—bone cancer	0.0113	0.0113	CcSEcCtD
Clavulanate—Hepatitis—Methotrexate—bone cancer	0.0113	0.0113	CcSEcCtD
Clavulanate—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.0108	0.0108	CcSEcCtD
Clavulanate—Hypersensitivity—Cisplatin—bone cancer	0.0108	0.0108	CcSEcCtD
Clavulanate—Erythema multiforme—Methotrexate—bone cancer	0.0107	0.0107	CcSEcCtD
Clavulanate—Haemoglobin—Epirubicin—bone cancer	0.0106	0.0106	CcSEcCtD
Clavulanate—Haemorrhage—Epirubicin—bone cancer	0.0105	0.0105	CcSEcCtD
Clavulanate—Hepatitis—Epirubicin—bone cancer	0.0105	0.0105	CcSEcCtD
Clavulanate—Diarrhoea—Cisplatin—bone cancer	0.00999	0.00999	CcSEcCtD
Clavulanate—Erythema multiforme—Epirubicin—bone cancer	0.00998	0.00998	CcSEcCtD
Clavulanate—Haemoglobin—Doxorubicin—bone cancer	0.00981	0.00981	CcSEcCtD
Clavulanate—Hepatitis—Doxorubicin—bone cancer	0.00976	0.00976	CcSEcCtD
Clavulanate—Haemorrhage—Doxorubicin—bone cancer	0.00976	0.00976	CcSEcCtD
Clavulanate—Vomiting—Cisplatin—bone cancer	0.00928	0.00928	CcSEcCtD
Clavulanate—Erythema multiforme—Doxorubicin—bone cancer	0.00923	0.00923	CcSEcCtD
Clavulanate—Rash—Cisplatin—bone cancer	0.0092	0.0092	CcSEcCtD
Clavulanate—Dermatitis—Cisplatin—bone cancer	0.00919	0.00919	CcSEcCtD
Clavulanate—Leukopenia—Methotrexate—bone cancer	0.00878	0.00878	CcSEcCtD
Clavulanate—Nausea—Cisplatin—bone cancer	0.00867	0.00867	CcSEcCtD
Clavulanate—Convulsion—Methotrexate—bone cancer	0.0085	0.0085	CcSEcCtD
Clavulanate—Leukopenia—Epirubicin—bone cancer	0.00822	0.00822	CcSEcCtD
Clavulanate—Anaphylactic shock—Methotrexate—bone cancer	0.00801	0.00801	CcSEcCtD
Clavulanate—Convulsion—Epirubicin—bone cancer	0.00796	0.00796	CcSEcCtD
Clavulanate—Thrombocytopenia—Methotrexate—bone cancer	0.00784	0.00784	CcSEcCtD
Clavulanate—Leukopenia—Doxorubicin—bone cancer	0.00761	0.00761	CcSEcCtD
Clavulanate—Anaphylactic shock—Epirubicin—bone cancer	0.0075	0.0075	CcSEcCtD
Clavulanate—Convulsion—Doxorubicin—bone cancer	0.00736	0.00736	CcSEcCtD
Clavulanate—Thrombocytopenia—Epirubicin—bone cancer	0.00734	0.00734	CcSEcCtD
Clavulanate—Anaphylactic shock—Doxorubicin—bone cancer	0.00694	0.00694	CcSEcCtD
Clavulanate—Pain—Methotrexate—bone cancer	0.00685	0.00685	CcSEcCtD
Clavulanate—Thrombocytopenia—Doxorubicin—bone cancer	0.00679	0.00679	CcSEcCtD
Clavulanate—Pain—Epirubicin—bone cancer	0.00641	0.00641	CcSEcCtD
Clavulanate—Urticaria—Methotrexate—bone cancer	0.00636	0.00636	CcSEcCtD
Clavulanate—Urticaria—Epirubicin—bone cancer	0.00595	0.00595	CcSEcCtD
Clavulanate—Pain—Doxorubicin—bone cancer	0.00593	0.00593	CcSEcCtD
Clavulanate—Hypersensitivity—Methotrexate—bone cancer	0.0059	0.0059	CcSEcCtD
Clavulanate—Pruritus—Methotrexate—bone cancer	0.00567	0.00567	CcSEcCtD
Clavulanate—Hypersensitivity—Epirubicin—bone cancer	0.00552	0.00552	CcSEcCtD
Clavulanate—Urticaria—Doxorubicin—bone cancer	0.00551	0.00551	CcSEcCtD
Clavulanate—Diarrhoea—Methotrexate—bone cancer	0.00548	0.00548	CcSEcCtD
Clavulanate—Pruritus—Epirubicin—bone cancer	0.0053	0.0053	CcSEcCtD
Clavulanate—Diarrhoea—Epirubicin—bone cancer	0.00513	0.00513	CcSEcCtD
Clavulanate—Hypersensitivity—Doxorubicin—bone cancer	0.00511	0.00511	CcSEcCtD
Clavulanate—Vomiting—Methotrexate—bone cancer	0.00509	0.00509	CcSEcCtD
Clavulanate—Rash—Methotrexate—bone cancer	0.00505	0.00505	CcSEcCtD
Clavulanate—Dermatitis—Methotrexate—bone cancer	0.00505	0.00505	CcSEcCtD
Clavulanate—Pruritus—Doxorubicin—bone cancer	0.00491	0.00491	CcSEcCtD
Clavulanate—Vomiting—Epirubicin—bone cancer	0.00477	0.00477	CcSEcCtD
Clavulanate—Nausea—Methotrexate—bone cancer	0.00476	0.00476	CcSEcCtD
Clavulanate—Diarrhoea—Doxorubicin—bone cancer	0.00475	0.00475	CcSEcCtD
Clavulanate—Rash—Epirubicin—bone cancer	0.00473	0.00473	CcSEcCtD
Clavulanate—Dermatitis—Epirubicin—bone cancer	0.00472	0.00472	CcSEcCtD
Clavulanate—Nausea—Epirubicin—bone cancer	0.00445	0.00445	CcSEcCtD
Clavulanate—Vomiting—Doxorubicin—bone cancer	0.00441	0.00441	CcSEcCtD
Clavulanate—Rash—Doxorubicin—bone cancer	0.00437	0.00437	CcSEcCtD
Clavulanate—Dermatitis—Doxorubicin—bone cancer	0.00437	0.00437	CcSEcCtD
Clavulanate—Nausea—Doxorubicin—bone cancer	0.00412	0.00412	CcSEcCtD
